Sign In
Buy HOTH
$1.36
+0 (+0%)
At Close: Jun 03, 2026
Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment
11:05am, Friday, 26'th Feb 2021
NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its licensing agreement from North Carolina State Universit
NEW YORK, Feb. 23, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and
Hoth Therapeutics Plans To Test HT-003 API In Inflammatory Bowel Disorders; Shares Spike
09:27am, Thursday, 18'th Feb 2021
Hoth Therapeutics Inc (NASDAQ: HOTH) plans to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel disease
Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv
01:30pm, Wednesday, 10'th Feb 2021
NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member, Michael Peter, Ph.D., published a wh
Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients
02:52pm, Monday, 08'th Feb 2021
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed an agreement with Camargo Pharmaceutical Services to faci
Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication
08:38am, Wednesday, 20'th Jan 2021
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to bloc
NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation License Agree
Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment
08:01am, Thursday, 31'st Dec 2020
NEW YORK, Dec. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials as
Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients
09:55am, Wednesday, 23'rd Dec 2020
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Fo
Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans
10:11am, Thursday, 10'th Dec 2020
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to co
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its
Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine
10:16am, Monday, 02'nd Nov 2020
NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the novel COVI
We're Keeping An Eye On Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate
04:34pm, Wednesday, 19'th Aug 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Hoth Therapeutics Provides Shareholder Update on COVID-19 Initiatives and Dermatological Therapy Pipeline
01:08pm, Wednesday, 19'th Aug 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today is providing shareholders with a update on its COVID-19 initiatives including vaccine and real-time, breath-based mobile test
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic BioLexa fo
